PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$6.81
+0.14 (+2.10%)
Open$6.82
Previous Close$6.67
Day High$6.92
Day Low$6.63
52W High$11.62
52W Low$3.01
Volume—
Avg Volume7.67M
Market Cap1.34B
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+148.9% upside
Current
$6.81
$6.81
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 243.91M | 233.99M | 197.33M |
| Net Income | 21.63M | 22.04M | 17.71M |
| Profit Margin | 8.9% | 9.4% | 9.0% |
| EBITDA | 48.94M | 46.22M | 40.39M |
| Free Cash Flow | 24.46M | 20.15M | 20.27M |
| Rev Growth | -3.3% | +11.1% | +4.4% |
| Debt/Equity | 0.58 | 0.61 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |